Co-Authors
This is a "connection" page, showing publications co-authored by Stefano Rusconi and Giuliano Rizzardini.
Connection Strength
0.893
-
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018 12; 19(6):242-248.
Score: 0.199
-
Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Ann Pharmacother. 2018 08; 52(8):740-746.
Score: 0.189
-
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data. BMC Infect Dis. 2017 09 30; 17(1):658.
Score: 0.184
-
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J Med Virol. 2021 03; 93(3):1421-1427.
Score: 0.057
-
Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis. 2020 07 28; 71(15):889-890.
Score: 0.056
-
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol Res. 2020 08; 158:104931.
Score: 0.055
-
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020 08; 158:104899.
Score: 0.055
-
Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy. J Med Virol. 2020 Sep; 92(9):1637-1640.
Score: 0.055
-
Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther. 2017; 22(3):273-275.
Score: 0.043